| Literature DB >> 34029690 |
Yongzhi Gao1, Nathaniel I Martin2, Matthijs J van Haren3.
Abstract
Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide (NA) to generate 1-methyl nicotinamide. Since its discovery 70 years ago, the appreciation of the role of NNMT in human health has evolved from serving only metabolic functions to also being a driving force in diseases, including a variety of cancers. Despite the increasing evidence indicating NNMT as a viable therapeutic target, the development of cell-active inhibitors against this enzyme is lacking. In this review, we provide an overview of the current status of NNMT inhibitor development, relevant in vitro and in vivo studies, and a discussion of the challenges faced in the development of NNMT inhibitors.Entities:
Keywords: Cancer; Inhibitors; Metabolic disorder; NNMT; Neurodegenerative disease; Nicotinamide; S-adenosyl-l-methionine
Mesh:
Substances:
Year: 2021 PMID: 34029690 DOI: 10.1016/j.drudis.2021.05.011
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851